Medipex-supported company secures essential role in Long-COVID research project

21 July 2021

Professor Paul O'Brien, CEO of Elaros is delighted to be able to announce his company's involvement in a successful government-backed initiative, the LOCOMOTION (LOng COVID Multidisciplinary consortium: Optimising Treatments and servIces acrOss the NHS) study which has been awarded £3.4 million.

The project is led by The University of Leeds which is funded by the National Institute for Health Research (NIHR). The study, led by Dr Manoj Sivan, aims to establish a gold standard of care for the treatment of long COVID patients that can be shared across the UK.

The research consortium includes 8 UK Universities including Imperial College, King's College, The University of Oxford, and 10 clinical sites across all 4 U.K. nations, with ELAROS named as an industrial partner that will provide its C19-YRS app and research platform to all 10 research sites. The aim is to gather large amounts of patient data quickly to help the consortium devise ways of supporting the nearly 2 million long Covid patients in the UK, and to further validate the C19-YRS scale to develop a standardised approach.

It is hoped also that this high profile project will lead to significant interest in ELAROS's clinical version of the C19-YRS system which is already being used in four NHS Hospitals (beyond Leeds) since the system went live in June 2021. 

Medipex have been providing business support and advice for many years to Elaros 24/7 and are delighted to support this latest initiative which delivers a new resource in the NHS fight against COVID19.

For additional information, please visit www.elaros.com.